The Phase II grant will provide the company with funding to develop a commercial-ready version of the test.
The HIV test is the first of several NGS-based infectious disease tests the company plans to develop, with a hepatitis C virus test following close behind.
Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The assay is intended for early infant diagnosis of HIV infection.
The fully automated self-confirming assay will simultaneously detect HIV/AIDS antibodies and viral RNA in a single specimen.
University Hospitals' Deepgen HIV assay will use Advanced Biological Laboratories' DeepChek software to help monitor drug resistance and minority variants in HIV strains.
The real-time PCR assay is designed to detect and identify HIV, hepatitis B virus, and hepatitis C virus in donations of human whole blood and blood components.
Shipping of the assay, Cepheid's eighth product release in 2014, is anticipated to begin in February 2015.
With the precision of PCR, the method could ultimately be used to build faster, simpler diagnostics.
The new claims allow for pre-transplantation testing of organ and tissue donations for HIV, hepatitis B virus, hepatitis C virus, and West Nile virus.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.